MINNEAPOLIS, Nov. 5, 2013 /PRNewswire/ -- CVRx, Inc., a private medical device company, and DaVita®, a division of DaVita HealthCare Partners Inc, have embarked on a strategic partnership. This partnership was established in conjunction with CVRx's Series F $42 million financing in which DaVita HealthCare Partners Inc. was recently added as a new investor. Under the partnership, the two companies will collaborate on commercial activities and clinical research intended to make CVRx's Barostim Therapy™ available to new patient populations.
"We're delighted to welcome DaVita into our investor syndicate and are excited to work together with DaVita and its affiliate, DaVita Clinical Research®, a specialty contract research organization with deep scientific and operational experience in renal disease trials," said Robert Kieval, Founder and Chief Technology Officer of CVRx. "Given their demonstrated commitment to medical innovation and advancing patient care, we are proud to have DaVita as a partner as we continue forward."
"Our focus is to collaborate on innovative approaches to addressing the complex clinical problems of patients with kidney disease to improve the quality of their lives," said Allen R.Nissenson, MD FACP, Chief Medical Officer for DaVita. "We believe the Barostim platform meets those criteria and therefore has the potential to provide both meaningful clinical benefits to patients and economic benefits to the health care system."
About DaVita
DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of kidney care in the United States, DaVita delivers dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients' quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of June 30, 2013, DaVita operated or provided administrative services at 2,010 outpatient dialysis centers located in the United States serving approximately 159,000 patients. The company also operated 48 outpatient dialysis centers located in ten countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company's leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit DaVita.com.
About CVRx, Inc.
CVRx, Inc. is a privately-held company founded in 2001 and is headquartered in Minneapolis. The company has developed the second generation Barostim neo™, an implantable system designed to treat hypertension (high blood pressure) and heart failure. In Europe, Barostim neo received CE marking for the treatment of hypertension and is in clinical evaluation for the treatment of heart failure. In the United States Barostim neo is in clinical evaluation for the treatment of heart failure and hypertension. For more information, visit Cvrx.com.
About Barostim neo
Barostim neo is a second generation device that uses CVRx-patented technology that is designed to trigger the body's own natural blood flow regulation system to treat hypertension and heart failure. The system works by electrically activating the baroreceptors, the body's natural blood pressure sensors that regulate cardiovascular function. These baroreceptors are located on the carotid artery. When activated by Barostim neo, signals are sent through neural pathways to the brain, which responds by telling the:
- Arteries to relax, making it easier for blood to flow through the body and reducing cardiac exertion;
- Heart to slow down, allowing more time for the organ to fill with blood; and
- Kidneys to reduce fluid in the body, lowering both excessive blood pressure and workload on the heart.
This unique, patented technology has the potential to improve quality of life and reduce health risks associated with hypertension and heart failure, including heart and kidney disease, stroke and death. Other key potential benefits of Barostim neo include the following:
- Can be adjusted to meet each patient's individual therapy needs, making it the only personalized medical device therapy for the treatment of hypertension with a CE marking;
- Is a non-destructive reversible treatment; and
- Provides 100% compliance to treatment, by automatically and continuously activating the baroreflex.
CAUTION: Barostim neo is an investigational device and is limited by United States law to investigational use.
CVRx, Barostim Therapy and Barostim neo are trademarks of CVRx, Inc. registered in the United States Trademark Office.
DaVita and DaVita HealthCare Partners are trademarks or registered trademarks of DaVita HealthCare Partners Inc.
© CVRx, Inc. 2013. All rights reserved.
SOURCE CVRx, Inc.
Share this article